Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans.
The immunologic basis for the potential enhanced HIV-1 acquisition in adenovirus serotype 5 (Ad5)-seropositive individuals who received the Merck recombinant Ad5 HIV-1 vaccine in the STEP study remains unclear. Here we show that baseline Ad5-specific neutralizing antibodies are not correlated with Ad5-specific T lymphocyte responses and that Ad5-seropositive subjects do not develop higher vector-specific cellular immune responses as compared with Ad5-seronegative subjects after vaccination. These findings challenge the hypothesis that activated Ad5-specific T lymphocytes were the cause of the potential enhanced HIV-1 susceptibility in the STEP study.
O'Brien
Kara L
KL
Division of Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Liu
Jinyan
J
King
Sharon L
SL
Sun
Ying-Hua
YH
Schmitz
Joern E
JE
Lifton
Michelle A
MA
Hutnick
Natalie A
NA
Betts
Michael R
MR
Dubey
Sheri A
SA
Goudsmit
Jaap
J
Shiver
John W
JW
Robertson
Michael N
MN
Casimiro
Danilo R
DR
Barouch
Dan H
DH
D016915:AIDS Vaccines / Q000276:immunology* / Q000627:therapeutic use*; D000163:Acquired Immunodeficiency Syndrome / Q000276:immunology / Q000628:therapy*; D000256:Adenoviridae / Q000276:immunology*; D000914:Antibodies, Viral / Q000032:analysis / Q000097:blood; D000918:Antibody Specificity / Q000276:immunology; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D007114:Immunization; D007371:Interferon-gamma / Q000378:metabolism; D037182:T-Cell Antigen Receptor Specificity / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology / Q000378:metabolism; D014614:Vaccines, Synthetic / Q000276:immunology / Q000627:therapeutic use
D016915:AIDS Vaccines; D000914:Antibodies, Viral; D014614:Vaccines, Synthetic; D007371:Interferon-gamma